WO2023073392 - BIOMARKERS AND USES THEREFOR
National phase entry is expected:
Publication Number
WO/2023/073392
Publication Date
04.05.2023
International Application No.
PCT/IB2021/000750
International Filing Date
29.10.2021
Title **
[English]
BIOMARKERS AND USES THEREFOR
[French]
BIOMARQUEURS ET LEURS UTILISATIONS
Applicants **
GENODX
54 Hewlett Street
Bronte, New South Wales 2024, AU
Inventors
RAPISARDA, Antony
54 Hewlett Street
Bronte, New South Wales 2024, AU
FOX, Brian, Andrew
2312 N. 39th Street
Seattle, WA 98103, US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP Australia
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4886 | |
| EPO | Filing, Examination | 94772 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 482 | |
| USA | Filing, Examination | 28760 |
Total: 129495 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed are biomarkers of inflammatory disease. More particularly, the present disclosure relates to biomarkers and their use in methods, compositions, apparatuses, devices and kits for determining an indicator that is useful for assessing a likelihood that a type of inflammation is present or absent in a joint of a subject.[French]
L'invention concerne des biomarqueurs de maladie inflammatoire. Plus particulièrement, la présente invention concerne des biomarqueurs et leur utilisation dans des procédés, des compositions, des appareils, des dispositifs et des kits pour déterminer un indicateur qui est utile pour évaluer une probabilité qu'un type d'inflammation soit présent ou absent dans une articulation d'un sujet.